Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines

ESMO Guidelines Committee; P. Ravasco

doi:10.1016/j.esmoop.2021.100092

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines

ESMO Guidelines Committee
, P. Ravasco

Research output: Contribution to journal › Article › peer-review

451 Citations (Scopus)

23 Downloads

Original language	English
Article number	100092
Number of pages	18
Journal	ESMO Open
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.esmoop.2021.100092
Publication status	Published - 1 Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Assessment
Cachexia
Cancer
Clinical practice guidelines
Nutrition
Treatment

Access to Document

10.1016/j.esmoop.2021.100092Licence: CC BY-NC-ND

32360301Final published version, 707 KBLicence: CC BY-NC-ND

http://hdl.handle.net/10400.14/34064Licence: CC BY-NC-ND

Cite this

@article{1aeb7569d7564050b7150e649bb78748,

title = "Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines",

keywords = "Assessment, Cachexia, Cancer, Clinical practice guidelines, Nutrition, Treatment",

author = "\{ESMO Guidelines Committee\} and J. Arends and F. Strasser and S. Gonella and Solheim, \{T. S.\} and C. Madeddu and P. Ravasco and L. Buonaccorso and Schueren, \{M. A. E. de van der\} and C. Baldwin and M. Chasen and Ripamonti, \{C. I.\}",

note = "Funding Information: Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. FS reports receipt of unrestricted industry grants to institute for clinical research from Celgene, Fresenius and Helsinn, participation in company-led clinical cachexia trials for Novartis and participation in an advisory role for Helsinn, Mundipharma, Novartis, Fresenius and Kaiku Health (reimbursements to institute); TSS reports receipt of honoraria from Fresenius Kabi; MC reports receipt of payment from Tetra Biopharmaceuticals for helping to write research protocols; JA reports receipt of consultancy fees from Baxter and Danone and honoraria from Berg-Apotheke, Falk, Fresenius Kabi, Nutricia and Roche; CIR reports receipt of funding for independent educational events from Inpharm, Kyowa Kirin, Amgen Europe and Molteni SpA; MAEdvdS reports receipt of honoraria for independent lectures at educational and scientific events organised by Nutricia, Fresenius Kabi and Baxter; all other authors have declared no conflicts of interest. Funding Information: Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO. ",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/j.esmoop.2021.100092",

language = "English",

volume = "6",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Cancer cachexia in adult patients

T2 - ESMO Clinical Practice Guidelines

AU - ESMO Guidelines Committee

AU - Arends, J.

AU - Strasser, F.

AU - Gonella, S.

AU - Solheim, T. S.

AU - Madeddu, C.

AU - Ravasco, P.

AU - Buonaccorso, L.

AU - Schueren, M. A. E. de van der

AU - Baldwin, C.

AU - Chasen, M.

AU - Ripamonti, C. I.

N1 - Funding Information: Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. FS reports receipt of unrestricted industry grants to institute for clinical research from Celgene, Fresenius and Helsinn, participation in company-led clinical cachexia trials for Novartis and participation in an advisory role for Helsinn, Mundipharma, Novartis, Fresenius and Kaiku Health (reimbursements to institute); TSS reports receipt of honoraria from Fresenius Kabi; MC reports receipt of payment from Tetra Biopharmaceuticals for helping to write research protocols; JA reports receipt of consultancy fees from Baxter and Danone and honoraria from Berg-Apotheke, Falk, Fresenius Kabi, Nutricia and Roche; CIR reports receipt of funding for independent educational events from Inpharm, Kyowa Kirin, Amgen Europe and Molteni SpA; MAEdvdS reports receipt of honoraria for independent lectures at educational and scientific events organised by Nutricia, Fresenius Kabi and Baxter; all other authors have declared no conflicts of interest. Funding Information: Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.

PY - 2021/6/1

Y1 - 2021/6/1

KW - Assessment

KW - Cachexia

KW - Cancer

KW - Clinical practice guidelines

KW - Nutrition

KW - Treatment

UR - https://www.scopus.com/pages/publications/85107286168

U2 - 10.1016/j.esmoop.2021.100092

DO - 10.1016/j.esmoop.2021.100092

M3 - Article

C2 - 34144781

AN - SCOPUS:85107286168

SN - 2059-7029

VL - 6

JO - ESMO Open

JF - ESMO Open

IS - 3

M1 - 100092

ER -

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines

UN SDGs

Keywords

Access to Document

Other files and links

CIIS: Center for Interdisciplinary Research in Health

Cite this

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines

UN SDGs

Keywords

Access to Document

Other files and links

Projects

CIIS: Center for Interdisciplinary Research in Health

Cite this